Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations
Key Highlights
- ➤All In reported net sales $989 million, down 5.2% year-over-year
- ➤All In adjusted diluted EPS $0.60, down 25.0% year-over-year
- ➤Infant Formula divestiture offers up to $175 million, including $40 million upfront
- ➤Fourth-quarter impairment loss expected between $275.0 million and $375.0 million
- ➤Fiscal 2026 All In adjusted EPS outlook $2.25 to $2.45
Expert Statements
Albert Manzone, Interim President and Chief Executive Officer of Perrigo
“Our Three-S plan is delivering continued progress in the areas of the business within our control”
Albert Manzone, Interim President and Chief Executive Officer of Perrigo
“We gained market share again in U.S. store brand OTC and in key European brands. Category trends improved sequentially, which, combined with disciplined cost management, helped offset a difficult consumer backdrop.”
Albert Manzone, Interim President and Chief Executive Officer of Perrigo
“The sale of Infant Formula is an important step in evolving Perrigo into a more focused consumer self-care company. It is expected to enhance our margin profile, materially reduce expected future capital expenditures, and support continued deleveraging and reinvestment in the business. The result will be a simpler Perrigo, better positioned for profitable growth.”
Albert Manzone, Interim President and Chief Executive Officer of Perrigo
“We have adjusted our full-year outlook to reflect the divestiture, more measured retailer inventory positioning ahead of the cough and cold season, and continued softness in Europe. Our underlying model, combining scaled brands and store brands in categories people need every day, remains unchanged, and the actions we are taking to simplify Perrigo are positioning us for more consistent and profitable growth over the long term.”
Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations PR Newswire
* Execution of Three-S plan driving sequential improvement in operating results and market share gains across U.S. Store Brand OTC and key European brands * Infant Formula divestiture expected to simplify portfolio and sharpen focus on higher-return consumer self care categories; strategic review of Oral Care business remains ongoing * Updated full-year 2026 outlook to reflect divestiture, more measured retailer inventory positioning, and continued softness in Europe DUBLIN, Nov. 4, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of consumer self-care products, today announced financial results from continuing operations for the third quarter ended September 26, 2026.
Get started
Create a free account to read the full story.